Food & Drug of counsel and former Acting and Deputy Director of FDA’s Office of Dietary Supplement Programs Bob Durkin was interviewed by NTD News’ Miguel Moreno on FDA’s seizure of a shipment of Ivermectin, a controversial COVID treatment that FDA opposes.
A Notice of FDA Action document stated “the drugs violated two requirements related to misbranding by having a lack of adequate directions for use and not including ‘Rx only’ on its label.”
“Essentially that charge just means that the box for the labeling of the drug did not have FDA-approved labeling on it,” said Bob.
Bob goes on to explain that FDA has been very clear it does not support the off-label use of Ivermectin.
Watch the full interview here.